康华生物：万可欣及其相关的产业生态资源将从研发、市场、战略、管理等维度对公司形成全链条赋能

Core Viewpoint - Kanghua Biotech's controlling shareholder is Wanke Xin, who has no actual controller, and the company will benefit from a full-chain empowerment across various dimensions including R&D, market, strategy, and management [1] R&D - The company will leverage Wanke Xin's resources to enhance its research capabilities, facilitating the clinical advancement of products under development and optimizing the product pipeline layout [1] Market - Wanke Xin will promote resource synergy to expand market coverage and enhance brand influence [1] Strategy - The collaboration will assist the company in clarifying its medium to long-term development direction and solidifying its growth path [1] Management - The partnership aims to drive improvements in the company's governance structure and enhance operational management efficiency [1]